Access cutting-edge al amyloidosis treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access al amyloidosis specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related al amyloidosis treatment provided free
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make
Sponsor: SWOG Cancer Research Network
Check if you qualify for this al amyloidosis clinical trial in New Haven, CT
If you're searching for al amyloidosis treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced al amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.